| Liu, Hong |
NCT06142552: Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein |
|
|
| Recruiting | 3 | 120 | RoW | FRSW117, Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 01/26 | 09/26 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
NCT04836520: SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer. |
|
|
| Completed | 2 | 20 | RoW | SHR6390+anatrozole | Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 02/23 | 03/23 | | |
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis |
|
|
| Active, not recruiting | 2 | 112 | Europe, US, RoW | Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Myelofibrosis | 01/25 | 01/25 | | |
|
|
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
NCT05881655: Slow Myopia Progression With Different Irradiance Light |
|
|
| Recruiting | N/A | 75 | RoW | Airdoc Red Lighting Device, Repeated Red Light, Low Lever Laser Therapy, Low Intensity Light Therapy, Photobiomodulation Therapy, Seconee, 650nm Red Light, Special Spectacles to Control Myopia, Essilor® Stellest™ Lenses, H.A.L.T lens | Beijing Airdoc Technology Co., Ltd., Shanghai Children's Medical Center | Myopia, Progressive | 05/24 | 12/25 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
| Zhang, Jian |
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. |
|
|
| Recruiting | 3 | 1600 | RoW | rhNRG-1, Neucardin™, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Heart Failure | 02/26 | 02/26 | | |
TQB2450-III-09, NCT04964479: A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) |
|
|
| Recruiting | 3 | 375 | RoW | TQB2450 injection, Anlotinib Hydrochloride Capsules, Pembrolizumab injection, Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 12/22 | 03/23 | | |
NCT06143553: Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 168 | RoW | Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection, Paclitaxel (albumin-bound) | Shanghai Yizhong Pharmaceutical Co., Ltd. | Metastatic Breast Cancer (MBC) | 12/25 | 12/25 | | |
NCT05949801: Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure |
|
|
| Completed | 3 | 202 | RoW | Neucardin, Recombinant human Neuregulin-1 for Injection, Placebo, Excipients of recombinant human neuregulin-1 freeze dried for injection | Zensun Sci. & Tech. Co., Ltd. | Chronic Systolic Heart Failure | 08/24 | 10/24 | | |
| Recruiting | 3 | 224 | RoW | DB-1303/BNT323, T-DM1 | DualityBio Inc., BioNTech SE | HER2-positive Breast Cancer | 02/26 | 02/26 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
GenSci093-301, NCT06449027: Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects. |
|
|
| Not yet recruiting | 3 | 200 | RoW | T Leuprolide Injectable Emulsion, Tamoxifen Citrate Tablets, Leuprorelin Acetate Microspheres for Injection | Changchun GeneScience Pharmaceutical Co., Ltd. | Breast Cancer Subjects | 11/25 | 03/26 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
NCT06382142: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer |
|
|
| Recruiting | 3 | 406 | RoW | BL-B01D1, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Triple-Negative Breast Cancer | 06/26 | 06/26 | | |
NCT06519370: FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | FDA018-ADC, FDA018-Antibody-drug Conjugate, Eribulin, Halaven, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Triple Negative Breast Cancer | 08/26 | 06/27 | | |
NCT06680921: A Study of SIM0270 Combined with Everolimus Vs. Treatment of Physician's Choice in Patients with ER+/HER2- Advanced Breast Cancer (SIMRISE) |
|
|
| Recruiting | 3 | 460 | RoW | SIM0270, Everolimus (Afinitor®), Exemestane tablets, Fulvestrant injection | Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing Zaiming Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 08/28 | 08/28 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
NCT04778982: Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer |
|
|
| Terminated | 2 | 4 | RoW | KN026 combined with Palbociclib and Fulvestrant, combination | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | HER2-positive Metastatic Breast Cancer | 03/23 | 03/23 | | |
NCT06413615: A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 150 | RoW | FDA022-BB05 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/25 | 06/26 | | |
NCT06492005: A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer |
|
|
| Recruiting | 2 | 160 | RoW | 9MW2821, PD-1 inhibitior | Mabwell (Shanghai) Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 07/26 | 07/27 | | |
NCT06471205: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 52 | RoW | BL-B01D1, PD-1 Monoclonal Antibody | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Triple-negative Breast Cancer | 07/26 | 07/26 | | |
NCT06042894: A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 58 | RoW | BL-B01D1, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd. | Breast Cancer | 12/25 | 12/25 | | |
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 114 | RoW | TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer | 09/24 | 12/24 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT05785728: A Study of DB-1202 Monotherapy in Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 150 | RoW | DB-1202 | DualityBio Inc. | Advanced Solid Tumor | 02/24 | 02/24 | | |
NCT04282031: A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer |
|
|
| Recruiting | 1/2 | 224 | RoW | BPI-1178, Fulvestrant, Letrozole | Beta Pharma (Suzhou) Co., Ltd. | Advanced Solid Tumor, HR+/HER2- Breast Cancer | 12/24 | 06/25 | | |
| Recruiting | 1/2 | 181 | US, RoW | MRG004A | Shanghai Miracogen Inc. | Advanced or Metastatic Solid Tumors | 04/24 | 06/25 | | |
NCT05048160: A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm |
|
|
| Recruiting | 1/2 | 272 | RoW | Intravenous Infusion | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Malignant Neoplasm | 06/24 | 12/24 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
| Recruiting | 1/2 | 404 | US, RoW | Rina-S, PRO1184, Rinatabart sesutecan, GEN1184, Carboplatin, Bevacizumab, Pembrolizumab | Genmab | Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer | 04/26 | 10/26 | | |
NCT05301764: A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma |
|
|
| Recruiting | 1/2 | 65 | RoW | LVGN6051 and Anlotinib | Lyvgen Biopharma Holdings Limited | Soft Tissue Sarcoma | 03/25 | 10/25 | | |
NCT05803018: A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies |
|
|
| Recruiting | 1/2 | 32 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Gynecological Malignant Tumor, Solid Tumor | 06/25 | 06/25 | | |
NCT05842785: TSN222 in Subjects With Advanced Solid Tumors or Lymphomas |
|
|
| Recruiting | 1/2 | 162 | RoW | Phase I dose escalation, Phase II-HNSCC, Phase II-Advanced melanoma, Phase II-solid tumors or lymphomas | Tyligand Bioscience (Shanghai) Limited | Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | 06/25 | 06/26 | | |
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 902 | US, RoW | DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327 | DualityBio Inc., BioNTech SE | Advanced Solid Tumor | 06/25 | 06/25 | | |
| Recruiting | 1/2 | 208 | RoW | 9MW2821 | Mabwell (Shanghai) Bioscience Co., Ltd. | Solid Tumors | 12/25 | 12/25 | | |
NCT05416749: A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 216 | RoW | 8MW2311 | Mabwell (Shanghai) Bioscience Co., Ltd. | Solid Tumors | 03/26 | 03/26 | | |
NCT05463432: A Study of HR19024 in Subjects With Advanced Solid Tumor |
|
|
| Recruiting | 1a | 180 | RoW | HR19024 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/23 | 07/23 | | |
| Completed | 1 | 23 | RoW | Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002., Biological Products, Humanized Anti-HER2 Monoclonal Antibody Compound for Injection | Shanghai Pharmaceuticals Holding Co., Ltd | Recurrent Breast Cancer, Metastatic Breast Cancer | 04/22 | 04/22 | | |
| Recruiting | 1 | 150 | RoW | GQ1005 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | HER2 Expressing or Mutated Advanced Malignant Solid Tumors | 12/24 | 07/25 | | |
NCT06299124: A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors |
|
|
| Recruiting | 1 | 40 | RoW | RGT-419B, Active drug | Regor Pharmaceuticals Inc. | Breast Cancer, Advanced Solid Tumor | 12/24 | 06/25 | | |
NCT04631835: Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer |
|
|
| Recruiting | 1 | 54 | RoW | HS-10352 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Breast Cancer | 04/23 | 08/23 | | |
NCT05221385: Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma |
|
|
| Terminated | 1 | 58 | RoW | Gentulizumab | Changchun GeneScience Pharmaceutical Co., Ltd. | Solid Tumor, Non-Hodgkin Lymphoma | 05/23 | 10/23 | | |
NCT05078593: A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma |
|
|
| Completed | 1 | 18 | RoW | HLX26, Anti-LAG-3 Monoclonal Antibody | Shanghai Henlius Biotech | Solid Tumor, Adult, Lymphoma | 08/23 | 08/23 | | |
| Completed | 1 | 28 | RoW | AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus | AstraZeneca | ER+, HER2-, Metastatic Breast Cancer | 09/23 | 09/23 | | |
NCT05337657: A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer |
|
|
| Recruiting | 1 | 10 | RoW | GB491+Letrozole | Genor Biopharma Co., Ltd. | Advanced Breast Cancer | 12/23 | 02/24 | | |
NCT06761651: A Study of TAVO412 in Patients with Cancer (TAVO412) |
|
|
| Recruiting | 1 | 50 | RoW | TAVO412 | Tavotek Biotherapeutics | Cancer | 01/26 | 10/26 | | |
NCT06172322: A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer |
|
|
| Recruiting | 1 | 42 | RoW | NTQ1062 with Fulvestrant | Nanjing Chia-tai Tianqing Pharmaceutical | HR Positive/HER-2 Negative Breast Cancer | 04/25 | 07/25 | | |
NCT05360368: HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors |
|
|
| Not yet recruiting | 1 | 24 | RoW | HLX07, Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection | Shanghai Henlius Biotech | Solid Tumor | 12/23 | 02/24 | | |
| Recruiting | 1 | 177 | RoW | HS-20089 (Phase Ia：Dose escalation ), HS-20089 (Phase Ib: Dose expansion) | Shanghai Hansoh Biomedical Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
| Recruiting | 1 | 156 | US, RoW | CS5001 | CStone Pharmaceuticals | Advanced Solid Tumor, Advanced Lymphoma | 03/25 | 06/25 | | |
|
NCT05263180: A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. |
|
|
| Recruiting | 1 | 30 | RoW | EMB-09 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Advanced Solid Tumor | 12/23 | 12/24 | | |
NCT05498597: AMT-151 in Patients With Selected Advanced Solid Tumours |
|
|
| Recruiting | 1 | 30 | RoW | AMT-151 | Multitude Therapeutics Inc., Tigermed Consulting Co., Ltd | Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer, Ovarian Carcinoma, Ovarian Epithelial Cancer, Ovarian Endometrioid Adenocarcinoma, Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Lung Adenocarcinoma, Triple Negative Breast Cancer, Pancreatic Ductal Adenocarcinoma, Malignant Pleural Mesothelioma, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Mucinous Adenocarcinoma | 01/24 | 10/24 | | |
NCT06219356: A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas |
|
|
| Recruiting | 1 | 110 | RoW | GLB-002, GLB-A062-B | Hangzhou GluBio Pharmaceutical Co., Ltd. | Non-Hodgkin Lymphoma | 01/26 | 02/27 | | |
NCT04586335: Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. |
|
|
| Terminated | 1 | 24 | US, RoW | CYH33, Olaparib | Haihe Biopharma Co., Ltd. | Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer | 02/23 | 02/23 | | |
NCT05509790: A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer |
|
|
| Active, not recruiting | 1 | 17 | RoW | LY3484356 | Eli Lilly and Company | Breast Neoplasms | 02/24 | 12/25 | | |
| Recruiting | 1 | 66 | RoW | Q-1802 | QureBio Ltd. | Advanced Solid Tumors | 04/24 | 07/24 | | |
NCT04893759: A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors |
|
|
| Recruiting | 1 | 60 | RoW | Pelcitoclax, APG-1252 | Ascentage Pharma Group Inc. | Neuroendocrine Tumors | 06/24 | 06/25 | | |
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation |
|
|
| Recruiting | 1 | 316 | RoW | HSK42360 | Haisco Pharmaceutical Group Co., Ltd. | Solid Tumors | 08/26 | 07/27 | | |
BL-B01D1-104, NCT05470348: A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Solid Tumor | 06/25 | 12/25 | | |
NCT05394168: A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 12 | RoW | HLX53 | Shanghai Henlius Biotech | Advanced/Metastatic Solid Tumors | 12/24 | 03/25 | | |
| Recruiting | 1 | 170 | RoW | SPH7485 | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumor | 12/27 | 12/27 | | |
BL-M17D1-101, NCT06503783: A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | BL-M17D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Solid Tumor | 08/26 | 08/26 | | |
BL-B16D1-103, NCT06493864: A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 21 | RoW | BL-B16D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Solid Tumor | 07/26 | 07/26 | | |
NCT05360381: HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 82 | RoW | HLX35 | Shanghai Henlius Biotech | Locally Advanced or Metastatic Solid Tumors, Squamous-cell Non-small Cell Lung Cancer | 10/24 | 12/24 | | |
NCT06426680: A Study of the ILB-3101 in Patients with Advanced Solid Tumors |
|
|
| Recruiting | 1 | 240 | RoW | ILB-3101 | Innolake Biopharm | Advanced Solid Tumor | 12/25 | 03/26 | | |
NCT06718621: A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Not yet recruiting | 1 | 22 | RoW | BL-M08D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Solid Tumor | 12/26 | 06/27 | | |
NCT06710158: Study of SC-102 in Patients with Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 120 | RoW | SC-102 | Tianjin ConjuStar Biologics Co., Ltd. | Advanced Solid Cancers | 12/26 | 06/27 | | |
NCT05631964: Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-M07D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Digestive Tract Tumors, Other Solid Tumors | 06/25 | 12/25 | | |
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer |
|
|
| Recruiting | 1 | 66 | US, RoW | INV-9956 | Shenzhen Ionova Life Sciences Co., Ltd. | Advanced Metastatic Castration Resistant Prostate Cancer | 04/26 | 03/27 | | |
NCT05787535: HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor |
|
|
| Recruiting | 1 | 17 | RoW | Fludarabine + Cyclophosphamide, HRYZ-T101 TCR-T Cell | HRYZ Biotech Co. | Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Cancer, Vagina Tumor, Carcinoma of Penis, Anal Carcinoma, Carcinoma of Vulva | 02/25 | 09/25 | | |
NCT05914376: Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors |
|
|
| Recruiting | 1 | 24 | RoW | Recombinant human IL-21-expressing oncolytic vaccinia virus injection, hV01 | Hangzhou Converd Co., Ltd. | Advanced Solid Tumors | 03/25 | 11/25 | | |
NCT05843305: A Study of BPI-452080 in Subjects With Solid Tumors |
|
|
| Not yet recruiting | 1 | 87 | RoW | BPI-452080 | Betta Pharmaceuticals Co., Ltd. | Solid Tumor, Renal Cell Carcinoma, Von Hippel-Lindau Disease | 03/25 | 10/25 | | |
NCT06094777: A Study of HY-0102 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 50 | RoW | HY-0102 | Shanghai YingLi Pharmaceutical Co. Ltd. | Advanced Solid Tumor | 06/25 | 12/25 | | |
| Recruiting | 1 | 20 | RoW | Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection | Fudan University, Cellular Biomedicine Group Ltd. | Cervical Cancer | 07/25 | 07/25 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
NCT05430373: GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors |
|
|
| Recruiting | 1 | 31 | RoW | GT101 | Grit Biotechnology | Solid Tumors, Adult | 08/25 | 12/25 | | |
NCT06064812: A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC. |
|
|
| Recruiting | 1 | 99 | RoW | FWD1802, palbocilib | Forward Pharmaceuticals Co., Ltd. | Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage I, ER+ Breast Cancer | 11/25 | 02/26 | | |
NCT05911217: A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer |
|
|
| Recruiting | 1 | 20 | RoW | CT041 autologous CAR T-cell injection, Single Group Assignment | CARsgen Therapeutics Co., Ltd., Fudan University | Pancreatic Cancer | 12/26 | 12/26 | | |
MEETCD8-001, NCT05707676: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（） |
|
|
| Recruiting | 1 | 66 | RoW | LB4330 | L & L biopharma Co., Ltd., Shanghai China | Solid Tumor | 09/25 | 09/26 | | |
NCT05952947: HRYZ-T101 Injection for HPV18 Positive Solid Tumor |
|
|
| Recruiting | 1 | 32 | RoW | HRYZ-T101 Injection, Fludarabine + Cyclophosphamide | HRYZ Biotech Co. | Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis, Anal Cancer, Carcinoma of Vulva | 12/27 | 02/28 | | |
| Recruiting | 1 | 78 | RoW | FDA018-ADC, FDA018-Antibody-drug Conjugate | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Advanced/ Metastatic Solid Tumors | 12/29 | 12/29 | | |
NCT03651986: Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules |
|
|
| Active, not recruiting | N/A | 10560 | RoW | ctDNA methylation analysis by NGS | AnchorDx Medical Co., Ltd., Xiangya Hospital of Central South University, West China Hospital, Shanghai Zhongshan Hospital, Shanghai Pulmonary Hospital affiliated to Tongji University, First Hospital of China Medical University, Guizhou Provincial People's Hospital, Shanghai Chest Hospital, First Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital Xi'an Jiaotong University, Qilu Hospital of Shandong University, Inner Mongolia People's Hospital, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Zhengzhou University, Second Hospital of Jilin University, LanZhou University, Peking University Third Hospital, The First People's Hospital of Yunnan, Shantou Affiliated Hospital of Sun Yat-Sen University, Ruijin Hospital, The Shanghai Jiao Tong University Medical School, Tongji Hospital, The First Affiliated Hospital of Guangzhou Medical University, Xijing Hospital, Air Force Medical University of PLA, Shenzhen People's Hospital, Henan Provincial People's Hospital, Beijing Chao Yang Hospital, Xiamen Second Hospital, The First Affiliated Hospital of Nanchang University | Pulmonary Nodules | 09/24 | 06/25 | | |
| Hou, Jie |
NCT06607380: A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine |
|
|
| Completed | 1 | 60 | RoW | TNM002, Adsorbed tetanus vaccine, TNM002 + adsorbed tetanus vaccine | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Tetanus | 04/23 | 04/23 | | |
NCT05186285: Single Ascending Dose Study of CM338 in Healthy Volunteers |
|
|
| Completed | 1 | 66 | RoW | CM338, Placebo | Keymed Biosciences Co.Ltd | Healthy | 07/22 | 07/22 | | |
| Enrolling by invitation | 1 | 36 | RoW | ZV0203 | Hangzhou Adcoris Biopharmacy Co., Ltd | HER2-positive Advanced Solid Tumor | 05/23 | 07/24 | | |
NCT05127772: A Clinical Trial of HEC93077 in Chinese Healthy Subjects and HUA Patients With Single or Multiple Dosing |
|
|
| Recruiting | 1 | 126 | RoW | HEC93077, Placebo | Sunshine Lake Pharma Co., Ltd. | Gout | 10/23 | 11/23 | | |
| Completed | 1 | 46 | RoW | CM326, Placebo | Keymed Biosciences Co.Ltd | Healthy | 10/23 | 10/23 | | |
| Recruiting | 1 | 40 | RoW | ZL-82, 600mg ZL-82, 50mg ZL-82, 100mg ZL-82, 200mg ZL-82, ZL-82 placebo, 600mg ZL-82 placebo, 50mg ZL-82 placebo, 100mg ZL-82 placebo, 200mg ZL-82 placebo | Chengdu Zenitar Biomedical Technology Co., Ltd | Healthy Person | 08/24 | 12/24 | | |
NCT05702450: Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310 |
|
|
| Completed | 1 | 240 | RoW | CM310 | Keymed Biosciences Co.Ltd | Healthy | 07/23 | 07/23 | | |
| Recruiting | 1 | 66 | RoW | Q-1802 | QureBio Ltd. | Advanced Solid Tumors | 04/24 | 07/24 | | |
NCT06379867: A Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects |
|
|
| Recruiting | 1 | 48 | RoW | HSK3486, Ciprofol, Placebo, Moxifloxacin | Haisco Pharmaceutical Group Co., Ltd. | Anesthesia | 05/24 | 08/24 | | |
| Lin, Wenhua |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Liu, Xiaocheng |
NCT06340048: Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure |
|
|
| Recruiting | 1/2 | 36 | RoW | HiCM-188 therapy | Help Therapeutics, TEDA International Cardiovascular Hospital | Heart Failure | 09/24 | 03/25 | | |
| Jing, Rui |
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus |
|
|
| Recruiting | N/A | 184 | RoW | Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter | Shanghai Bluesail Boyuan Medical Technology Co., Ltd. | Coronary Artery Disease, Intravascular Lithotripsy | 12/24 | 09/25 | | |
| Wu, Zhong |
NCT05898230: Retrospective Clinical Data Collection on Carbomedics OptiForm Mitral Heart Valve |
|
|
| Recruiting | N/A | 400 | RoW | Mitral Valve Replacement | Corcym S.r.l | Mitral Valve Disease | 12/24 | 12/24 | | |
| Xiao, Yongqi |
| No trials found |
| Yue, Hong-hua |
| No trials found |
